{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T00:21:31Z","timestamp":1771028491357,"version":"3.50.1"},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T00:00:00Z","timestamp":1624406400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Little is known about the outcome and prognostic factors of relapsed or refractory T\u2010cell lymphoblastic lymphoma (T\u2010LBL), especially in adult patients. The aim of this study was to analyze the characteristics, outcome and prognostic factors for this patient population.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Between January 2006 and December 2017, we retrospectively analyzed 84\u00a0adult patients with T\u2010LBL, and 44 relapsed or primary refractory patients were included in this analysis. Clinical features, treatment and follow\u2010up information were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>For all 44 patients, the median time to disease progression or relapse was 9.5 months after diagnosis. At a median follow\u2010up of 19.6 months, 40 (90.9%) patients died. The 3\u2010 and 5\u2010year overall survival (OS) rates after disease progression or relapse were 7.8% and 5.2%, respectively. Among 30 patients who had detailed information of second\u2010line treatment, only eight achieved a second complete remission (CR). Two of these eight patients subsequently underwent autologous or allogeneic stem cell transplantation (SCT), of whom one died from disease progression after autologous SCT, and one was free of event at 84\u00a0months after allogeneic SCT. Three of the rest six patients in second CR were still alive after chemotherapy alone. All the remaining patients who failed to gain second CR eventually died. In univariate analysis, only the achievement of second CR was positively predictive of OS (hazard ratio (HR)\u00a0=\u00a00.307; 95% confidence interval (CI), 0.104\u20130.905; <jats:italic>P<\/jats:italic>\u00a0=\u00a00.032).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The outcome of adult patients with relapsed or refractory T\u2010LBL is extremely dismal. Patients with relapsed or refractory T\u2010LBL should be encouraged to participate in clinical trials where novel therapeutic approaches are available.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.13562","type":"journal-article","created":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T17:59:26Z","timestamp":1624471166000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Dismal outcome of relapsed or primary refractory adult T\u2010cell lymphoblastic lymphoma: A retrospective study from China"],"prefix":"10.1111","volume":"18","author":[{"given":"Haizhu","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianliang","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"He","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengyu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changgong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8685-6744","authenticated-orcid":false,"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital Chinese Academy of Medical Sciences &amp; Peking Union Medical College Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs  Beijing China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,6,23]]},"reference":[{"key":"e_1_2_13_2_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0b013e31826b1232"},{"issue":"12","key":"e_1_2_13_3_1","first-page":"1015","article-title":"Treatment of lymphoblastic lymphoma in adults","volume":"23","author":"Sweetenham JW","year":"2009","journal-title":"Oncology (Williston Park)"},{"key":"e_1_2_13_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_13_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16998"},{"key":"e_1_2_13_6_1","first-page":"JCO2000531","article-title":"Successful outcomes of newly diagnosed T lymphoblastic lymphoma: Results from Children's Oncology Group AALL0434","author":"Hayashi RJ","year":"2020","journal-title":"J Clin Oncol"},{"key":"e_1_2_13_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-01-0110"},{"key":"e_1_2_13_8_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10882"},{"key":"e_1_2_13_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404156"},{"key":"e_1_2_13_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1992.10.7.1078"},{"key":"e_1_2_13_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-12-4428"},{"key":"e_1_2_13_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15793"},{"key":"e_1_2_13_13_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.3367"},{"key":"e_1_2_13_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25990"},{"key":"e_1_2_13_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"issue":"11","key":"e_1_2_13_16_1","first-page":"1860","article-title":"Report of the Committee on Hodgkin's Disease Staging Classification","volume":"31","author":"Carbone PP","year":"1971","journal-title":"Cancer Res"},{"key":"e_1_2_13_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_13_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_13_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403095"},{"key":"e_1_2_13_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.02.011"},{"key":"e_1_2_13_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.61.5385"},{"key":"e_1_2_13_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.21941"},{"key":"e_1_2_13_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058107"},{"key":"e_1_2_13_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1994.12.7.1358"},{"key":"e_1_2_13_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-05-1483"},{"issue":"2","key":"e_1_2_13_26_1","first-page":"416","article-title":"Intensive ALL\u2010type therapy without local radiotherapy provides a 90% event\u2010free survival for children with T\u2010cell lymphoblastic lymphoma: A BFM group report","volume":"95","author":"Reiter A","year":"2000","journal-title":"Blood"},{"key":"e_1_2_13_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_2_13_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14874"},{"key":"e_1_2_13_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23167"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13562","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ajco.13562","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.13562","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T11:10:58Z","timestamp":1692961858000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.13562"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,23]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1111\/ajco.13562"],"URL":"https:\/\/doi.org\/10.1111\/ajco.13562","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,23]]},"assertion":[{"value":"2020-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}